Glaxosmithkline Share Price | |
---|---|
Price | 1,618.50 |
Bid | 1,618.50 |
Ask | 1,619.00 |
Change | -21.50 (-1.31%) |
Volume | 924,072 |
Open | 1,633.00 |
High | 1,641.00 |
Low | 1,616.00 |
Prev. Close | 1,640.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.08b |
Market Capitalisation | £66.00b |
Market Size | 1,500 |
52 Week High | 1,820.00 |
52 Week High Date | 15-May-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 2,671 |
---|---|
Vol. Sold | 474,886 |
Sold Value | £7.73m |
Vol. Bought | 431,465 |
Bought Value | £7.02m |
PE Ratio | 13.31003 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.429% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
07-Jun-24 | 11:15:46 | 1,616.106 | 73 | Sell* | 1,618.00 | 1,618.50 | 1,180 | O Ordinary |
07-Jun-24 | 11:15:44 | 1,617.00 | 1,087 | Sell* | 1,618.00 | 1,618.50 | 17.58k | O Ordinary Trade was executed as an SI |
07-Jun-24 | 11:15:44 | 1,618.00 | 98 | Unknown* | 1,618.00 | 1,618.50 | 1,586 | O Ordinary Was reported as OTC |
07-Jun-24 | 11:15:44 | 1,618.00 | 476 | Buy* | 1,617.50 | 1,618.00 | 7,702 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 280 | Buy* | 1,617.50 | 1,618.00 | 4,530 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 58 | Buy* | 1,617.50 | 1,618.00 | 938.44 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 234 | Buy* | 1,617.50 | 1,618.00 | 3,786 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 100 | Buy* | 1,617.50 | 1,618.00 | 1,618 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 37 | Buy* | 1,617.50 | 1,618.00 | 598.66 | A Automatic Execution |
07-Jun-24 | 11:15:44 | 1,618.00 | 372 | Buy* | 1,617.50 | 1,618.00 | 6,019 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
20-May-24 | 16-May-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 44.88 | USD | 2,433 | 3,373,198 |
20-May-24 | 16-May-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 4,488.00 | GBX | 61 | 3,373,198 |
14-May-24 | 10-May-24 | Transfer From | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 0.00 | 7 | 41,995 | |
14-May-24 | 10-May-24 | Buy | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 1,794.34 | GBX | 7 | 41,995 |
14-May-24 | 10-May-24 | Transfer From | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 0.00 | 7 | 2,190,863 |
At GSK, we unite science, technology and talent to get ahead of disease together